123 related articles for article (PubMed ID: 9848448)
41. Efficacy of 2-(3,4-dimethyl-2,5-dihydro-1h-pyrrole-2-yl)-1-methylethyl pentanoate in a murine model of invasive aspergillosis.
Dabur R; Diwedi SK; Yadav V; Mishra V; Singh R; Singh H; Sharma GL
Antimicrob Agents Chemother; 2005 Oct; 49(10):4365-7. PubMed ID: 16189123
[TBL] [Abstract][Full Text] [Related]
42. Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.
López-Sánchez A; Pérez-Cantero A; Torrado-Salmerón C; Martin-Vicente A; García-Herrero V; González-Nicolás MÁ; Lázaro A; Tejedor A; Torrado-Santiago S; García-Rodríguez JJ; Capilla J; Torrado S
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760126
[TBL] [Abstract][Full Text] [Related]
43. Treatment of experimental murine aspergillosis with BAY n7133.
Graybill JR; Kaster SR; Drutz DJ
J Infect Dis; 1983 Nov; 148(5):898-906. PubMed ID: 6313822
[TBL] [Abstract][Full Text] [Related]
44. Antifungal and immunomodulatory activity of a novel cochleate for amphotericin B delivery against Sporothrix schenckii.
Batista-Duharte A; Lastre M; Romeu B; Portuondo DL; Téllez-Martínez D; Manente FA; Pérez O; Carlos IZ
Int Immunopharmacol; 2016 Nov; 40():277-287. PubMed ID: 27639705
[TBL] [Abstract][Full Text] [Related]
45. Reducing the toxicity of amphotericin B by encapsulation using methoxy poly(ethylene glycol)-b-poly(l-glutamic acid-co-l-phenylalanine).
Yang C; Xue B; Song W; Kan B; Zhang D; Yu H; Shen N; Li X; Tang Z; Chen X
Biomater Sci; 2018 Jul; 6(8):2189-2196. PubMed ID: 29947373
[TBL] [Abstract][Full Text] [Related]
46. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
47. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.
Patterson TF; Miniter P; Dijkstra J; Szoka FC; Ryan JL; Andriole VT
J Infect Dis; 1989 Apr; 159(4):717-24. PubMed ID: 2926162
[TBL] [Abstract][Full Text] [Related]
48. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.
Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y
Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats.
Ullmann AJ; Krammes E; Sommer S; Buschmann I; Jahn-Muehl B; Cacciapuoti A; Schmitt HJ
J Antimicrob Chemother; 2007 Nov; 60(5):1080-4. PubMed ID: 17855727
[TBL] [Abstract][Full Text] [Related]
50. SCH56592 treatment of murine invasive aspergillosis.
Graybill JR; Bocanegra R; Najvar LK; Luther MF; Loebenberg D
J Antimicrob Chemother; 1998 Oct; 42(4):539-42. PubMed ID: 9818757
[TBL] [Abstract][Full Text] [Related]
51. In situ liposomal preparation containing amphotericin B: related toxicity and tissue disposition studies.
Chakraborty KK; Naik SR
Pharm Dev Technol; 2000; 5(4):543-53. PubMed ID: 11109253
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
53. Design of liposomes to improve delivery of amphotericin-B in the treatment of aspergillosis.
Ahmad I; Sarkar AK; Bachhawat BK
Mol Cell Biochem; 1989 Nov 23-Dec 19; 91(1-2):85-90. PubMed ID: 2695834
[TBL] [Abstract][Full Text] [Related]
54. Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis.
Owais M; Ahmed I; Krishnakumar B; Jain RK; Bachhawat BK; Gupta CM
FEBS Lett; 1993 Jul; 326(1-3):56-8. PubMed ID: 8325389
[TBL] [Abstract][Full Text] [Related]
55. The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection.
Alsaadi M; Italia JL; Mullen AB; Ravi Kumar MN; Candlish AA; Williams RA; Shaw CD; Al Gawhari F; Coombs GH; Wiese M; Thomson AH; Puig-Sellart M; Wallace J; Sharp A; Wheeler L; Warn P; Carter KC
J Control Release; 2012 Jun; 160(3):685-91. PubMed ID: 22516093
[TBL] [Abstract][Full Text] [Related]
56. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
[TBL] [Abstract][Full Text] [Related]
57. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus.
Otsubo T; Maesaki S; Hossain MA; Yamamoto Y; Tomono K; Tashiro T; Seki J; Tomii Y; Sonoke S; Kohno S
Antimicrob Agents Chemother; 1999 Mar; 43(3):471-5. PubMed ID: 10049253
[TBL] [Abstract][Full Text] [Related]
58. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF.
Sionov E; Mendlovic S; Segal E
J Antimicrob Chemother; 2005 Sep; 56(3):594-7. PubMed ID: 16006446
[TBL] [Abstract][Full Text] [Related]
59. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice.
van Etten EW; van den Heuvel-de Groot C; Bakker-Woudenberg IA
J Antimicrob Chemother; 1993 Nov; 32(5):723-39. PubMed ID: 8125837
[TBL] [Abstract][Full Text] [Related]
60. Treatment of murine systemic aspergillosis with polyene-intralipid admixtures.
Sionov E; Segal E
Med Mycol; 2004 Feb; 42(1):73-80. PubMed ID: 14982116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
